| 15.95 0.5 (3.24%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.89  |
1-year : | 21.12 |
| Resists | First : | 17.02 |
Second : | 18.09 |
| Pivot price | 16.13 |
|||
| Supports | First : | 15.31 |
Second : | 12.74 |
| MAs | MA(5) : | 15.84 |
MA(20) : | 16.23 |
| MA(100) : | 18.56 |
MA(250) : | 16.5 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 14.7 |
D(3) : | 12.6 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 26.35 | Low : | 5.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NAMS ] has closed above bottom band by 35.4%. Bollinger Bands are 55.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.29 - 16.4 | 16.4 - 16.49 |
| Low: | 15.06 - 15.19 | 15.19 - 15.31 |
| Close: | 15.74 - 15.95 | 15.95 - 16.15 |
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Tue, 17 Sep 2024
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Fri, 06 Sep 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Fri, 06 Sep 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Wed, 28 Aug 2024
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga
Wed, 28 Aug 2024
Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
Tue, 30 Jul 2024
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results (CORRECTED) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 3.389e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 1,400 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0863e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 306.9 % |
| Return on Equity (ttm) | -27.2 % |
| Qtrly Rev. Growth | 7.42e+006 % |
| Gross Profit (p.s.) | 3270 |
| Sales Per Share | -5408 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -189 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.87e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|